Invokana Lawsuit Attorneys at Bernstein Liebhard LLP Note Australian Ketoacidosis Advisory for SGLT2 Inhibitor Type 2 Diabetes Drugs

September 2, 2015 - Australian drug regulators have issued an alert regarding the possibility that Type 2 diabetes drugs like Invokana (http://www.invokanalawsuitcenter.com/) may be associated with the onset of diabetic ketoacidosis, a potentially fatal complication. The August 13th notification from the Australian Therapeutic Goods Administration (TGA) was prompted by reports of the condition occurring among patients who were taking sodium glucose co-transporter 2 (SGLT2) inhibitors, a class of medications that includes Invokana, Forxiga, Xigduo XR and Jardiance. Patients using these drugs have been advised to seek medical advice if they experience abdominal pain, nausea, vomiting, anorexia, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness.

"The Australian TGA is just the latest regulator to issue a warning regarding the possible link between Type 2 diabetes drugs like Invokana and ketoacidosis. Our Firm has been contacted by a number of patients who allegedly experienced this complication while being treated with these medications, and we are pleased that this important public health issue is receiving the attention it deserves," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is investigating potential Invokana lawsuits on behalf of Type 2 diabetes patients who were diagnosed with ketoacidosis, allegedly due to their use of this or another SGLT2 inhibitor.

FDA Safety Alert
In May, the U.S. Food & Drug Administration (FDA) announced that its adverse event database had received 20 reports of ketoacidosis (reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis) in patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014. Since June 2014, additional reports have been logged with the agency. The FDA is currently reviewing this issue in order to determine whether changes are needed in the prescribing information for SGLT2 inhibitors.

In June, the European Medicines Agency issued a similar notification. According to its EudraVigilance database, a total of 101 cases of ketoacidosis have been reported worldwide as of May 2015 in patients treated with SGLT2 inhibitors for Type 2 diabetes.

Ketoacidosis is a life-threatening complication that occurs when the body produces excessive levels of blood acids called ketones. All of the cases reported so far in relation to SGLT2 inhibitors required emergency treatment, and some resulted in hospitalization. While ketoacidosis generally affects Type 1 diabetes, regulators in the U.S. and elsewhere have noted that most of the reports involving SGLT2 inhibitors occurred in Type 2 diabetics. The cases were also unusual in that blood sugar levels, when reported, were only slightly elevated.

Individuals who were hospitalized with diabetic ketoacidosis that may be related to their use of Invokana or another SGLT2 inhibitor could be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. To find out more about filing an Invokana lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.invokanalawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author